Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms

Gary KL Chan,Samantha Maisel,Yeonjoo C Hwang,Bryan C Pascual,Rebecca RB Wolber,Phuong Vu,Krushna C Patra,Mehdi Bouhaddou,Heidi L Kenerson,Huat C Lim,Donald Long,Raymond S Yeung,Praveen Sethupathy,Danielle L Swaney,Nevan J Krogan,Rigney E Turnham,Kimberly J Riehle,John D Scott,Nabeel Bardeesy,John D Gordan

DOI: https://doi.org/10.7554/eLife.69521

IF: 7.7

2023-01-25

eLife

Abstract:Genetic alterations that activate protein kinase A (PKA) are found in many tumor types. Yet, their downstream oncogenic signaling mechanisms are poorly understood. We used global phosphoproteomics and kinase activity profiling to map conserved signaling outputs driven by a range of genetic changes that activate PKA in human cancer. Two signaling networks were identified downstream of PKA: RAS/MAPK components, and an Aurora Kinase A (AURKA) /glycogen synthase kinase (GSK3) sub-network with activity toward MYC oncoproteins. Findings were validated in two PKA-dependent cancer models: a novel, patient-derived fibrolamellar liver cancer (FLC) line that expresses a DNAJ-PKAc fusion, and a PKA-addicted melanoma model with a mutant Type I PKA regulatory subunit. We identify PKA signals that can influence both de novo translation and stability of the proto-oncogene c-MYC. However, the primary mechanism of PKA effects on MYC in our cell models was translation and could be blocked with the eIF4A inhibitor zotatifin. This compound dramatically reduced c-MYC expression and inhibited FLC cell line growth in vitro . Thus, targeting PKA effects on translation is a potential treatment strategy for FLC and other PKA-driven cancers.

biology